Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;8(6):1227-33.
doi: 10.21037/jtd.2016.04.60.

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

Qian-Li Ma  1 , Yong-Qing Guo  1 , Bin Shi  1 , Yan-Chu Tian  1 , Zhi-Yi Song  1 , De-Ruo Liu  1
Affiliations

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

Qian-Li Ma et al. J Thorac Dis. 2016 Jun.

Abstract

Background: Pneumonectomy (PN) has traditionally been the treatment of choice for central lung tumors for which the alternative is sleeve lobectomy (SL). The aim of this study was to compare early and long-term results after SL and PN in focusing on T3 central non-small cell lung cancer (NSCLC).

Methods: Patients who underwent SL (n=58) or PN (n=42) were retrospectively analyzed. For bias reduction, these 100 patients had been selected according to the following criteria: (I) tumor located in the main bronchus less than 2 cm distal to the carina; (II) there were no N2 disease; (III) no induction therapy was applied; (IV) complete resection (R0) was achieved.

Results: SL and PN patients had comparable mean ages, gender distribution, mean forced expiratory volume in 1 second (FEV1), stage and tumor grade. Postoperative mortality (3.4% vs. 4.8%, P=1.0) and morbidity (41% vs. 38%, P=0.74) were similar between the two groups. Recurrences occurred in 48% of patients after SL and in 31% of those after PN (P=0.08). The 5-year survival after SL (64.8%) and PN (61.4%) was not significantly different (P=0.20). Multivariable survival analysis showed that there were no independent prognostic factors.

Conclusions: SL does not compromise survival for NSCLC with T3 central disease compared with PN. It is an adequate oncologic resection and should be treated as the first line intervention whenever complete resection can be achieved.

Keywords: Sleeve lobectomy (SL); lung neoplasm; pneumonectomy (PN).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Survival curves stratified by sleeve lobectomy and pneumonectomy (P=0.204).
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. 10.3322/caac.20107 - DOI - PubMed
    1. Wain JC. Bronchoplastic Resections. In: Kaiser LR. editor. Mastery of Cardiothoracic Surgery. Philadelphia: Lippincott-Raven, 1998:68-76.
    1. Deslauriers J, Grégoire J, Jacques LF, et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg 2004;77:1152-6; discussion 1156. 10.1016/j.athoracsur.2003.07.040 - DOI - PubMed
    1. Ma Z, Dong A, Fan J, et al. Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis. Eur J Cardiothorac Surg 2007;32:20-8. 10.1016/j.ejcts.2007.03.018 - DOI - PubMed
    1. Bagan P, Berna P, Pereira JC, et al. Sleeve lobectomy versus pneumonectomy: tumor characteristics and comparative analysis of feasibility and results. Ann Thorac Surg 2005;80:2046-50. 10.1016/j.athoracsur.2005.06.045 - DOI - PubMed

LinkOut - more resources